Catalyst Capital Advisors LLC Lowers Stock Position in Cencora, Inc. (NYSE:COR)

Catalyst Capital Advisors LLC cut its stake in Cencora, Inc. (NYSE:COR - Free Report) by 83.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,563 shares of the company's stock after selling 23,848 shares during the quarter. Catalyst Capital Advisors LLC's holdings in Cencora were worth $1,025,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Lake Street Advisors Group LLC grew its holdings in shares of Cencora by 1.3% in the third quarter. Lake Street Advisors Group LLC now owns 3,415 shares of the company's stock valued at $769,000 after purchasing an additional 43 shares during the period. Venturi Wealth Management LLC grew its stake in shares of Cencora by 1.0% in the 3rd quarter. Venturi Wealth Management LLC now owns 4,447 shares of the company's stock valued at $1,001,000 after buying an additional 46 shares during the period. Prime Capital Investment Advisors LLC increased its holdings in shares of Cencora by 1.2% during the 3rd quarter. Prime Capital Investment Advisors LLC now owns 3,768 shares of the company's stock worth $848,000 after buying an additional 46 shares during the last quarter. Shepherd Financial Partners LLC raised its position in shares of Cencora by 0.9% during the 4th quarter. Shepherd Financial Partners LLC now owns 5,441 shares of the company's stock valued at $1,223,000 after buying an additional 46 shares during the period. Finally, WASHINGTON TRUST Co raised its position in shares of Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after buying an additional 46 shares during the period. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Stock Down 0.8 %

NYSE:COR traded down $1.99 during mid-day trading on Friday, hitting $241.47. The stock had a trading volume of 1,060,827 shares, compared to its average volume of 1,488,495. The stock has a 50-day simple moving average of $239.52 and a two-hundred day simple moving average of $237.46. The company has a market capitalization of $46.83 billion, a PE ratio of 34.35, a PEG ratio of 1.32 and a beta of 0.49. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $262.26. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR - Get Free Report) last issued its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, equities research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Shareholders of record on Friday, February 14th will be paid a $0.55 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $2.20 annualized dividend and a yield of 0.91%. Cencora's dividend payout ratio is currently 31.29%.

Analyst Upgrades and Downgrades

COR has been the subject of several research analyst reports. Barclays increased their target price on shares of Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. lifted their target price on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research report on Friday, January 24th. Mizuho began coverage on shares of Cencora in a research report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 price target on the stock. Robert W. Baird increased their price target on shares of Cencora from $287.00 to $292.00 and gave the stock an "outperform" rating in a research report on Thursday, November 7th. Finally, Evercore ISI increased their price target on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, Cencora presently has a consensus rating of "Moderate Buy" and a consensus price target of $277.90.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the transaction, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Chairman Steven H. Collis sold 50,000 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the transaction, the chairman now owns 326,557 shares in the company, valued at $79,670,111.29. This represents a 13.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 10.80% of the stock is currently owned by insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.